Skip to content

Imaging for SIJ Injection Therapy

The Clinic Application of CBCT XperGuide in Interventional Sacroiliac Joint Pain Therapy

Status
Withdrawn
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03992053
Enrollment
0
Registered
2019-06-19
Start date
2019-05-31
Completion date
2021-04-07
Last updated
2021-05-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sacroiliitis, Sacroiliac Joint Pain

Keywords

2-dimensional (2-D) fluoroscopy, 3-dimensional (3-D) Computed Tomography (CT) guidance, sacroiliac joint injection

Brief summary

The Research question: Among two standard image guidance techniques \[2-dimension (2-D) conventional Fluoroscopy Versus 3-dimension (3-D) Cone-Beam Computed Tomography (CBCT)\], which is the better guidance for Sacroiliac Joint Injection therapy and should be used first? The specific aims: To detect the difference of the first-time success rate, the cross-over rate, the procedural time, the radiation exposure, the incidence of adverse events/complications, and overall satisfaction score between the 2-D Fluoroscopy versus 3-D CBCT guidance for SIJ injection.

Detailed description

There are no published research studies comparing the injection success rates, procedure duration, radiation exposure, and patient comfort between the two standard imaging systems. The investigators hypothesize that the newer 3-D Cone-beam Based Computer Tomography (CBCT) image system will result in higher success rates, shorter procedure times, fewer image snapshots during the procedure, and less patient discomfort than conventional 2-D fluoroscopy imaging. Although the radiation exposure from one-time low-dose 3-D CT reconstruction with CBCT image system at the beginning of the procedure is higher, the number of later snapshots with the 3-D system is likely to be significantly lower. Therefore the 3-D system may result in overall equivalent radiation exposure to the 2-D system. A statistical power analysis was conducted and determined that a sample size of 100 (50 per group) will give 80% power for detecting a difference if the true rates are 65% (2-D Fluoroscopy guidance) and 90% (3-D CBCT guidance). For this study, patients undergoing SIJ injection will be randomized to either Fluoroscopy guidance or CBCT guidance. The primary outcome measure is injection success within 3 attempts of needle placement. Statistical analysis will use the Chi-square test to test whether the rate of injection success differs between the two methods of guidance. In order to provide appropriate clinical care, whenever success is not achieved with the initial guidance method then injection using the other guidance method will be attempted. However, the analysis will only consider whether or not injection success was achieved with the initial guidance method to which the subject was randomized. Whether or not injection success was achieved after crossing over to the other guidance method is not relevant to the primary analysis. In summary, the investigators would like to formally analyze the differences in these two standard image guidance options in SIJ injection therapy. The investigators propose to randomly select the first imaging system that will be utilized during standard medical care in patients scheduled to undergo an SIJ injection. Presumed that there is a difference in success rate between these two standard images, the imaging procedures are considered to be a part of the research.

Interventions

Image-guided sacroiliac joint injection under fluoroscopy or CT guidance and the success of intraarticular access was demonstrated by inter-articular contrast spread (the standard of care, not part of study intervention).

Sponsors

Philips Medical Systems
CollaboratorINDUSTRY
University of Washington
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
DIAGNOSTIC
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Age 18 and older 2. Clinically diagnosed with sacroiliac joint pain 3. Medically indicated for sacroiliac joint injection (SIJ) therapy (with chronic sacroiliac joint pain, debilitating with pain score \> 4 and not responsive to conservative medical management) 4. Financial pre-authorization of SIJ injection approved by insurance 5. English speaking 6. Scheduled for SIJ injection on the Allura machine

Exclusion criteria

1\. Patient refusal or inability to study informed consent

Design outcomes

Primary

MeasureTime frameDescription
The success rate of sacroiliac joint injectionduring the procedure periodsthe difference between the success rate of Sacroiliac Joint injection under 3-D CBCT and that of 2-D fluoroscopy guidance
The crossover rate from the first choice guidance to back-up guidanceduring the procedure periodsThe crossover rate from the first choice guidance to back-up guidance after three best attempts

Secondary

MeasureTime frameDescription
Procedure Durationduring the procedure periodsLength of time for procedure measured in minutes.
Incidence of Treatment-Emergent Adverse Eventsduring the procedure periodsTachycardia, hypertension, vasovagal reaction, procedural abortion, etc.
Procedure Radiation Doseduring the procedure periodsMeasurement of radiation dose in Rads during procedure.
Patient Satisfaction Scoreduring the procedure periodsProcedure Satisfaction Score measured on a 0-10 Visual Analog Scale. The left zero end represents not satisfied at all and the right 10 end represents 100% satisfaction.
Needle placement attemptsduring the procedure periodsNumber of attempts to place needle for procedure.
Procedure Painduring the procedure periodsPre-procedure typical baseline pain and post-procedure typical pain measured on a 0-10 Visual Analog Scale. This scale measures the pain intensity and percentage of pain relief. The left zero end represents no pain and right 10 end represents worst pain imaginable.
Procedure Contrast Doseduring the procedure periodsMeasurement of contrast dose in mL during procedure.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026